Viemed Healthcare (NASDAQ:VMD) Earns Outperform Rating from Analysts at Barrington Research

Investment analysts at Barrington Research assumed coverage on shares of Viemed Healthcare (NASDAQ:VMD) in a report issued on Monday. The brokerage set an “outperform” rating and a $14.00 price target on the stock. Barrington Research’s price target indicates a potential upside of 58.19% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the stock. Freedom Capital cut shares of Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Weiss Ratings lowered shares of Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Finally, Wall Street Zen cut shares of Viemed Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $14.00.

Viemed Healthcare Stock Performance

Shares of NASDAQ VMD opened at $8.85 on Monday. The business has a fifty day simple moving average of $10.98 and a 200 day simple moving average of $9.87. The company has a current ratio of 1.13, a quick ratio of 1.02 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $337.10 million, a price-to-earnings ratio of 24.58 and a beta of 1.10. Viemed Healthcare has a one year low of $6.05 and a one year high of $12.61.

Viemed Healthcare (NASDAQ:VMD) last issued its earnings results on Monday, August 3rd. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). Viemed Healthcare had a return on equity of 10.16% and a net margin of 4.81%.The firm had revenue of $78.10 million during the quarter, compared to the consensus estimate of $78.00 million. Sell-side analysts expect that Viemed Healthcare will post 0.42 EPS for the current year.

Insiders Place Their Bets

In other Viemed Healthcare news, Director Timothy Smokoff sold 20,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $11.50, for a total value of $230,000.00. Following the transaction, the director owned 75,518 shares of the company’s stock, valued at approximately $868,457. The trade was a 20.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Frazier sold 10,000 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $11.72, for a total value of $117,200.00. Following the sale, the insider owned 73,214 shares in the company, valued at $858,068.08. The trade was a 12.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its holdings in Viemed Healthcare by 189.0% during the 2nd quarter. California State Teachers Retirement System now owns 5,347 shares of the company’s stock worth $61,000 after acquiring an additional 3,497 shares during the last quarter. Susquehanna International Group LLP raised its stake in shares of Viemed Healthcare by 164.8% in the second quarter. Susquehanna International Group LLP now owns 75,429 shares of the company’s stock worth $860,000 after acquiring an additional 46,940 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Viemed Healthcare during the second quarter worth approximately $7,209,873,000. Kingsview Wealth Management LLC bought a new stake in shares of Viemed Healthcare during the second quarter valued at approximately $146,000. Finally, Raffles Associates LP bought a new stake in shares of Viemed Healthcare during the second quarter valued at approximately $4,602,000. Institutional investors and hedge funds own 74.24% of the company’s stock.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.